Source comparison
BPC-157 Safety According to Studies: Comparison
Acute Toxicity (LD50) No lethal dose identified at 10 mg/kg in rats. Significantly higher than therapeutic range (Chang et al., Journal of Physiology and Pharmacology) No human LD50 data exists. Extrapolation from animal models only Not evaluated by FDA for hu
This comparison does not assign a generated winner or score.
- Acute Toxicity (LD50)
- No lethal dose identified at 10 mg/kg in rats. Significantly higher than therapeutic range (Chang et al., Journal of Physiology and Pharmacology)
- No human LD50 data exists. Extrapolation from animal models only
- Not evaluated by FDA for human use
- Animal models suggest low acute toxicity, but species-specific differences in metabolism and receptor density make direct human extrapolation uncertain
- Organ Function (Liver, Kidney)
- No elevation in ALT, AST, creatinine after 28-day administration at 10 mcg/kg (Sikiric et al., 2020)
- Zero Phase I or II trials assessing hepatic or renal markers in humans
- No formal pharmacokinetic profile in human subjects
- Strong preclinical safety signal in rodents, but absence of human dosing data means organ-specific risks remain theoretical
- Chronic Toxicity (>90 Days)
- Longest published study: 12 weeks in rats. No adverse effects observed
- No long-term human trials of any duration
- Not classified as safe for chronic use by any regulatory authority
- Chronic safety is the largest evidence gap. Animal data does not extend to timeframes relevant for human therapeutic use
- Angiogenesis Concerns
- BPC-157 upregulates VEGF (vascular endothelial growth factor) in wound healing models. Mechanism beneficial for tissue repair but theoretically pro-tumorigenic in cancer contexts
- No human oncology trials; no data on cancer patients
- Contraindicated in populations with active malignancy (precautionary)
- VEGF upregulation is a double-edged mechanism. Beneficial for healing, but requires caution in individuals with cancer history or risk factors
- Immunogenicity
- No immune-mediated adverse events reported in animal studies
- No data on human immune response, antibody formation, or allergic reactions
- Unknown
- Peptides can trigger immune responses in humans that don't appear in animal models. This is a critical unknown
- Reproductive/Developmental Toxicity
- No teratogenicity studies published
- No data on pregnancy, lactation, or fetal development
- Not approved for use in pregnant or breastfeeding populations
- Complete data void. No basis for safety claims in reproductive contexts